Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03076567 · ClinicalTrials.gov registry record
Discovery and Validation of Plasma DNA Methylation Biomarker for Detection of Stomach Cancer
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 440
- Enrollment target
NCT03076567: Completed study, sponsored by National Cancer Institute (NCI).
NCT03076567 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 440 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03076567 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 440 participants
- Enrollment target
Study Summary
Background: Stomach cancer is common around the world. The US is a low-risk region. But the 5-year survival rate in the US is low. This is because the cancer is usually in a late stage by the time it is diagnosed. One way to detect it earlier is to screen many people with a procedure called endoscopy. But this may not be feasible in low-risk or developing countries. Researchers want to find a biomarker for early-stage disease to help them create an effective way of screening. DNA methylation is a chemical modification of DNA. It generates a signal for certain cancers, including stomach cancer. Researchers want to find a blood-based DNA methylation marker for stomach cancer. Objective: To study plasma DNA methylation as a potential biomarker for detection of stomach cancer. Eligibility: Participants from 2 studies already done in China Design: Researchers will use blood samples from participants in the 2 studies. The blood was collected in 1999/2000. They will use samples from some who developed stomach cancer between those years and 2006. The other samples will be from some who stayed cancer free in that time. Participants already gave written informed consent. Researchers will take DNA from the samples. They will look for methylation.
Primary Outcome
Relation of markers tested to cancer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2017-03-09 |
| Est. Completion | 2020-02-21 |
What the finished NCT03076567 record still lists
NCT03076567 is an observational study that tracks outcomes without assigning an intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03076567 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03076567 about?
NCT03076567 is a clinical study titled "Discovery and Validation of Plasma DNA Methylation Biomarker for Detection of Stomach Cancer". Background: Stomach cancer is common around the world. The US is a low-risk region. But the 5-year survival rate in the US is low. This is because the cancer is usually in a late stage by the time it is diagnosed. One way to detect it earlier is to screen many people with a procedure called endosco...
What is the current status of trial NCT03076567?
This trial is currently completed. The enrollment target is 440 participants. The study started on 2017-03-09. Estimated completion is 2020-02-21.
Who is sponsoring clinical trial NCT03076567?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
- NCT05624879 · 440 participants · NA
Accelerated Resolution Therapy for Early Maladaptive Grief
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI